Barr Pharmaceuticals receives authorization for generic Taxol injection Barr Pharmaceuticals, Inc.s., offers received final authorization from the U.S. Food and Medication Administration because of its generic edition of Bristol-Myers Squibb Company’s Taxol Injection USP, 6mg/mL, packaged in 100mg/16.7 mL and 300mg/50 mL Multiple-dose Vials. THE BUSINESS plans to start its product shortly. Barr’s U.S. Generic injectable portfolio totals seven products. Barr’s item will compete in market that got annual sales of around $98 million for the a year ended January 2008, predicated on IMS sales data.However, the dietary changes didn’t appear to prevent mice from developing some cognitive deficits associated with age, such as for example declines in memory. ‘Our results help us understand the processes underlying both normal maturing and calorie restriction benefits,’ says principal investigator Laura L. Dugan, M.D., associate professor of neurology, of medicine and of anatomy and neurobiology. ‘If some aspects of ageing are influenced by free radical damage, we might be able to prevent or reverse these impairments.’ Though numerous studies have shown severe calorie restriction helps pets live longer and withstand some effects of aging, scientists still do not know why. One theory suggests a restrictive diet decreases the result of free radical harm. Free of charge radicals are chemically reactive molecules produced either as byproducts of the body’s natural procedures or due to stress from the environment, like smog or sunlight.